Milan Facilities

 

Anything is possible

Any size company. Any phase. Any process. Any location in the world. Whatever your need, we are the CDMO that can get it done. Together, we have the power to change lives by transforming your vision into reality.

With state-of-the-art clinical and commercial manufacturing facilities across the United States, Europe and Asia, AGC Biologics has the capacity and flexibility to meet your individual manufacturing needs. We're here for you, wherever you are. 

  • Milan Facility

    Milan facility

  • North Milan Facility

    North Milan facility

Modalities

(Plasmid DNA offered from our  Heidelberg site)

 

Contact Us
Milan
Via Olgettina, 58
20132 Milan, Italy
Tel.+39 02 21277.1
Fax +39 02 21277.325

 

General Manager

Luca Alberici

 

Now Hiring

We’re looking for talented individuals – just like you – to join our team in Milan. We can't wait to meet you. Learn more and apply now:

Milan FACILITIES

The two facilities that make up AGC Biologics' Milan campus were the first cell and gene therapy facilities approved in Europe for GMP manufacturing of clinical and commercial supply (2003 and 2015, respectively).

AGC Biologics brings technical expertise to develop and optimize every aspect of cell therapy and viral vector gene therapy. Our services range from the production of plasmid DNA (at our Heidelberg facility), necessary for the transfection of cell production, to the engineering of cells through the use of produced viral vectors.

Our technical know-how allows us to bring small-scale platforms to scalable industrial manufacturing, ensuring process robustness and commercial viability. With experience manufacturing four commercial products, we are the only cell and gene therapy CDMO which has brought its own product to the market (Zalmoxis®).

[

GMP/QC Equipment and Technology

  • 2 site locations with 230+ experts in Milan & North Milan
  • 3 streams for 24L/48L lentiviral and retroviral vector manufacturing in cell factories
  • 1 stream for 200L lentiviral and retroviral vector manufacturing in a fixed-bed bioreactor
  • 9 Class B suites for engineered cells manufacturing and MCB/WCB/PPCB generation, equipped with cell enrichment/cell washing/cell expansion automated machines
  • 1 Class B suite for autologous/allogeneic genetically modified T-cells manufacturing
  • 1 Class C suite for automated fill & finish
  • 1 Class C suite for media preparation
  • > 35 labs in QC area for product testing and release
,

Development Area Equipment and Technology

  • Areas for small-, medium- and full-scale manufacturing of lentiviral and retroviral vectors, equipped with several small-scale fixed-bed bioreactors and stirred-tank bioreactors for upstream manufacturing and 4 different liquid chromatography systems and 3 different TFF systems for downstream processes

  • Areas for small-, medium- and large-scale engineered cell manufacturing, equipped with cell enrichment, cell washing and cell expansion automated machines 

  • Areas for analytical method development and qualification, including automated liquid handling systems

,

Ongoing Expansion

  • We're dedicated to continuous innovation, and as such, we constantly invest heavily in new technology, new modalities and new and expanding facilities, to stay ahead of our customer’s ever-evolving needs.
  • In recently shared expansion plans, we announced that we will add two additional floors to the suite and install additional equipment on the current floor in the Milan facility. The new facilities are scheduled to begin full operation in 2022.
  • In addition to continuously enhancing and extending capabilities in Milan, we will be establishing significant cell and gene therapy offerings in Seattle by late 2022/early 2023
]